HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.…
HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results
HCW Biologics (NASDAQ: HCWB) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 35 employees.
The shares were at 0.7491 USD on 20 November 2026, down 95.9% over 52 weeks. Its 52-week range is 0.7000 USD to 23.94 USD: the price is 96.9% below the high and 7.0% above the low.
Its market capitalisation is 2.35M USD.
HCW Biologics reports return on equity of -287.9% and an operating margin of -92.0%.
Its debt exceeds its cash by 5.82M USD, a debt-to-equity ratio of 2.46. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.